- Home
- LCTX vs DIBS Comparison
LCTX vs DIBS Comparison
Compare LCTX & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- DIBS
- Stock Information
- Founded
- LCTX 1990
- DIBS 2000
- Country
- LCTX United States
- DIBS United States
- Employees
- LCTX N/A
- DIBS 237
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- DIBS Catalog/Specialty Distribution
- Sector
- LCTX Health Care
- DIBS Consumer Discretionary
- Exchange
- LCTX Nasdaq
- DIBS Nasdaq
- Market Cap
- LCTX 127.7M
- DIBS 132.5M
- IPO Year
- LCTX N/A
- DIBS 2021
- Fundamental
- Price
- LCTX $0.61
- DIBS $3.63
- Analyst Decision
- LCTX Strong Buy
- DIBS Buy
- Analyst Count
- LCTX 5
- DIBS 2
- Target Price
- LCTX $4.80
- DIBS $8.00
- AVG Volume (30 Days)
- LCTX 2.4M
- DIBS 100.2K
- Earning Date
- LCTX 03-06-2025
- DIBS 02-26-2025
- Dividend Yield
- LCTX N/A
- DIBS N/A
- EPS Growth
- LCTX N/A
- DIBS N/A
- EPS
- LCTX N/A
- DIBS N/A
- Revenue
- LCTX $8,719,000.00
- DIBS $86,409,000.00
- Revenue This Year
- LCTX N/A
- DIBS $5.17
- Revenue Next Year
- LCTX $41.15
- DIBS $7.90
- P/E Ratio
- LCTX N/A
- DIBS N/A
- Revenue Growth
- LCTX N/A
- DIBS N/A
- 52 Week Low
- LCTX $0.48
- DIBS $3.37
- 52 Week High
- LCTX $1.61
- DIBS $6.30
- Technical
- Relative Strength Index (RSI)
- LCTX 52.01
- DIBS 48.31
- Support Level
- LCTX $0.55
- DIBS $3.56
- Resistance Level
- LCTX $0.60
- DIBS $3.70
- Average True Range (ATR)
- LCTX 0.04
- DIBS 0.11
- MACD
- LCTX 0.01
- DIBS 0.02
- Stochastic Oscillator
- LCTX 83.38
- DIBS 74.19
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.